Synthesis of novel selenotetrazole purine derivatives and their potential chemotherapeutic activities

• Published in: Medicinal chemistry research 2021, Vol.30 (1), p.84-97
• Main Authors: Dilek, Gulay, Tekin, Ishak Ozel, Coban, Burak, Disli, Ali, Gercek, Zuhal
• Format: Article
• Language: English
• Subjects: Anticancer properties; Antitumor agents; Biochemistry; Biomedical and Life Sciences; Biomedicine; Bioorganic Chemistry; Cancer; Cell cycle; Chemotherapy; Cytotoxicity; Deoxyribonucleic acid; DNA; DNA biosynthesis; Electrophoresis; Flow cytometry; Gel electrophoresis; Inorganic Chemistry; Lymphocytes; Lymphoma; Medicinal Chemistry; Melanoma; Mitosis; Original Research; Ovarian cancer; Peripheral blood; Pharmacology/Toxicology; Purines; Synthesis; Titration; Transcription; Tumor cell lines
• ISSN: 1054-2523; 1554-8120
• DOI: 10.1007/s00044-020-02641-1

The development of novel chemotherapeutic agents is indispensable to improve cancer treatment. One of the conventional approaches toward the synthesis of anticancer agents is the design of a compound whose structure is similar to purines found in DNA. In this study, a series of novel artificial purine nucleosides bearing selenotetrazole pharmacophore, 4a – 4h , were synthesized. In order to get preliminary information about their cytotoxic activities, the interaction of compounds with DNA was investigated by UV titration and agarose gel electrophoresis and transcription inhibition studies were performed. The cytotoxic effects of the compounds against B16 melanoma, OV90 ovarian cancer, JM1 lymphoma cell lines, and PHA-induced peripheral blood lymphocytes were also investigated. In cell assay studies, the effects of the compounds on synthesis and mitosis stage of cell cycle were compared by flow cytometry. Although none of the compounds synthesized interacted with DNA and exhibited transcription inhibition, all of them significantly inhibited DNA synthesis phase and showed cytotoxic activity on cancer and proliferating cells.